$GUTS

BRADLEY WILLIAM purchased $50K of GUTS

BRADLEY WILLIAM purchased 68,493 shares of FRACTYL HEALTH, INC. (GUTS) at $0.73 on 2026-06-10.

Original reporting
SEC EDGAR · BRADLEY WILLIAM
Published Jun 11, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GUTS
Bullish
medium confidence
Mentioned
$GUTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GUTSBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase (68,493 shares at $0.7348) and the resulting direct ownership increase to 84,622 shares.

02

Market read

Traders may view the filing as a small bullish sentiment datapoint, but it lacks fundamental catalysts (no guidance, trial, deal, or enforcement action).

03

What to watch

No 10b5-1 plan is stated, but the article provides no context on prior trading cadence, option exercises, or whether the director’s incentives/compensation changed.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-11; purchase dated 2026-06-10

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for FRACTYL HEALTH, INC. (GUTS).

Company-level read

Ticker impact

$GUTSBullishMedium confidence
Context

SEC Form 4 shows director Bradley William bought 68,493 shares of FRACTYL HEALTH (GUTS) for ~$50.3K on 2026-06-10, direct holdings increased to 84,622.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should be treated as low-conviction.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size (~$50K) is relatively small versus typical market-moving thresholds, and there is no accompanying operational/regulatory update.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/portfolio rebalancing and may not reflect near-term business improvement, especially at small dollar sizes.

Key entities

  • FRACTYL HEALTH, INC.

    Company whose shares were purchased by a director; insider transaction disclosed via SEC Form 4.

  • BRADLEY WILLIAM

    Director who purchased 68,493 shares on 2026-06-10; holdings increased to 84,622.

Related articles

MedAI 8/10

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Fractyl Health (

Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

$GUTSMed

Fractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up

Fractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.

$GUTSMedAI 8/10

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.